MedTrace Logo

Diagnostic Performance of Spot Urine Sample for the Monoclonal Components Detection in Patients With Multiple Myeloma

NCT05208086 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 180

Last updated 2026-04-13

No results posted yet for this study

Summary

The primary objective of the study is to evaluate at Day 1 Cycle 2, the detection sensitivity of the urinary monoclonal component on a spot urine sample, compared to the reference measurement on 24-hour urine, in patients with Multiple Myeloma.

Conditions

Interventions

DIAGNOSTIC_TEST

Detection of monoclonal component

Monoclonal component analysis by electrophoresis and immnuofixation on the urine sample from miction and 24h urine sample.

Sponsors & Collaborators

  • Intergroupe Francophone du Myelome

    lead NETWORK

Principal Investigators

  • Olivier DECAUX, PU-PH · Rennes University Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-05-18
Primary Completion
2026-05-31
Completion
2026-05-31

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05208086 on ClinicalTrials.gov